## CORRICULUM VITAE

(Updated June 2013)

# Amir Shlomai MD,PhD

#### Current address:

649 Ogden Ave Teaneck, NJ 07666, USA

Rice's Lab, Department of Virology and Infectious Disease, The Rockefeller University, NYC, NY, USA ashlomai@rockefeller.edu

#### Permanent Address:

47/22 Sara Immenu street Modiin, Israel

The Institute of Gastroenterology and Liver Diseases, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel amirsh@tasmc.health.gov.il

#### **Education**

**1.**Studies for **PhD degree**, Feinberg Graduate School of the Weizmann Institute of Science, Rehovot, Israel. Department of Molecular Genetics. <u>Research topic</u>: "PGC-1α- its role in HBV life cycle and its post-translational regulation by a metabolic circuit". <u>PI:</u> Prof. Yosef Shaul (2005-2008). **PhD degree, September 2008**.

2.Studies for MSc Graduate School of degree, Feinberg the Weizmann Institute of Science, Rehovot, Israel. Department of Molecular Research topic: "Inhibition of Hepatitis Genetics. В Expression Replication by RNA Interference". PI: Prof. Yosef Shaul (2002-2003). MSc degree (with distinction), November 2003.

**3.**Studies for **MD degree**, The Hebrew University, Jerusalem, Israel, Faculty of Medicine (1994-2001). **M.D degree, January 2002**.

# **Post Graduate Training**

- **1.**An **Instructor in Clinical Investigation**, clinical scholar program, the laboratory of virology and infectious diseases, the Rockefeller University, NYC, NY, USA. PI: Prof Charles M. Rice. (2012-)
- **2.Fellowship** in Gastroenterology and Liver Diseases at the institute of gastroenterology and liver diseases, Tel-Aviv Sourasky medical center (2009-2011).
- **3.Residency** in internal medicine, Department of Medicine B, Tel-Aviv Sourasky Medical center, Tel-Aviv (2008-2009) and Department of Medicine A, Hadassah University Hospital, Jerusalem (2003-2005).

#### **Honors** and awards

- **1.**Dean award for Excellency in first year studies- The Hebrew University Medical school (1994)
- **2.**Dean's prize of excellence for M.Sc students, Feinberg Graduate School, Weizmann Institute of Science (2003)
- **3.**Distinction in Internal Medicine Board exams (Stage B) (2009)

**4.**Included in the dean's list of best teachers, Sackler Faculty of Medicine, Tel-Aviv University (2010-2012)

### **Professional Licenses and Board Certifications:**

- **1.**Certified to practice **medicine**, the Israeli Ministry of Health (2002)
- **2.**Certified as a specialist in **Internal Medicine**, the Israeli Ministry of Health (2009)
- **3.**Certified as a specialist in **Gastroenterology and Liver Diseases**, the Israeli Ministry of Health (2012)
- **4.**Certified by the **ECFMG**, USA (2012)
- **5.**Limited permit to practice Medicine, NYS (Rockefeller University Hospital) (2012-2014)

## **Academic Appointments:**

- **1.Instructor in Clinical Investigation**, the Laboratory of Virology and Infectious Diseases, the Rockefeller University, NY, USA (2012-)
- **2.**A **Faculty member** at a **Lecturer** degree, the Sackler Faculty of Medicine, Tel-Aviv University (2010-)

# **Hospital Appointments:**

- **1.**A **senior physician**, the Institute of Gastroenterology and Liver Diseases, Tel-Aviv Sourasky Medical Center, Tel-Aviv,Israel (currently on a research vacation)
- **2.Head of a research group**, laboratory of gastroenterology and liver diseases, Tel-Aviv Sourasky Medical Center. Research topic: viral hepatitis and liver metabolism (2009-)

# Membership in professional societies and scientific journals

- **1.**Member of the American association for the study of liver diseases (AASLD)
- **2.**Member of the European association for the study of the liver (EASL)
- **3.**Member of the Israeli association for the study of liver diseases (IASLD)
- **4.**Member Association for Clinical and Translational Science (USA) (2013-)
- **5.**Member of the editorial board- *World Journal of Hepatology (WJH)* (2010)
- **6.**Contributing Associate Editors-in-Chief of the World Journal of Gastroenterology (WJG) (2011)
- 7. Member of the editorial board- *Journal of anti-virals and anti-retrovirals* (2011)
- **8.**Member of the Editorial Board- Liver International (2013-)

# Reviewer for journals and grants

- 1. Research grant from the chief scientist, the Israeli ministry of health
- **2.**Research grant from the Israeli cancer association (ICA)
- **3.**Research grant from the Israel Science Foundation (ISF)
- **4.**World journal of gastroenterology
- **5.**Digestive Diseases and Sciences
- **6.**Liver International
- 7. Plos Pathogens
- 8. J Viral Hepatitis

# Grants and fellowships

- 1.A physician-scientist grant, Hadassah Medical Center (2004)
- 2. Zalsberg grant, Hadassah Medical Center (2004)
- **3.**Adams fellowship for PhD students from the Israeli Academy of Science (2006)
- 4. The Weizmann-Ichilov joint grant (with Prof Y. Shaul) (2008)
- **5.**The Ichilov grant for excellence (2009)
- **6.**Israel Cancer Association (ICA) grant (with distinction) (2010)
- **7.**Schraiber grant from the Sackler Faculty of Medicine, Tel-Aviv University (2010)
- **8.**Maria Ascoli-Rossi grant from the Israeli Ministry of Justice (with Dr EH Sklan, TAU) (2011)
- **9.**A young researcher grant from the Israeli Society for the Study of the Liver (with Dr EH Sklan, TAU) (2012)
- **10.**CDDS pilot award, the Rockefeller University (2012)

## **Conference organization**

- **1.**The first Israeli conference of hepatitis viruses and HCC, May 2009, Tel-Aviv Sourasky Medical Center, Tel-Aviv.
- **2.**Chairperson and organizer of the clinical virology session, the annual conference of the Israeli Society of Microbiology (ISM), February 2010, Bar-Ilan University, Israel.
- **3.**The second Israeli conference of hepatitis viruses and HCC, June 2010, Tel-Aviv Sourasky Medical Center, Tel-Aviv.

## **Teaching Experience**

- **1.**Clinical teaching of medical students, Department of medicine B, Tel-Aviv Sourasky Medical Center
- **2.**Lecturer in the course "systems physiology", New-York program medical students, TAU. Lectures on the topics: "Physiology of the liver and the biliary system", "Physiology of the pancreas"
- **3.**Lecturer in the course "systems physiology", New-York program medical students, TAU. Lectures on the topics: "Physiology of the liver and the biliary system", "Physiology of the pancreas"
- **4.**Lecturer in the course "GI tract", the 4-year program of medical students, TAU. Lectures on the topics: "viral hepatitis", "cirrhosis and its complications", "acute hepatic failure"

# **Mentoring Students and Fellows**

- 1. Iddo Bar-Yishay (MS.c student, with Prof. Z. Halpern)
- 2. Olga Burdelova (Post-doc)

#### **Publications**

#### **Original peer-reviewed Articles**

- 1. Gotsman, I., **Shlomai, A.**, Alper, R., Rabbani, E., Engelhardt, D., and Ilan, Y. 2001. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect. *J Pharmacol Exp Ther* 297:926-932.
- 2. **Shlomai, A.**, Trop, S., Gotsman, I., Jurim, O., Diment, J., Alper, R., Rabbani, E., Engelhardt, D., and Ilan, Y. 2001. Immunomodulation of experimental colitis: the

- role of NK1.1 liver lymphocytes and surrogate antigens--bystander effect. *J Pathol* 195:498-507.
- 3. **Shlomai, A.**, and Shaul, Y. 2003. Inhibition of hepatitis B virus expression and replication by RNA interference. *Hepatology* 37:764-770.
- 4. **Shlomai, A.**, Paran, N., and Shaul, Y. 2006. PGC-1alpha controls hepatitis B virus through nutritional signals. *Proc Natl Acad Sci U S A* 103:16003-16008.
- 5. **Shlomai, A.**, and Shaul, Y. 2008. The "metabolovirus" model of hepatitis B virus suggests nutritional therapy as an effective anti-viral weapon. *Med Hypotheses* 71:53-57.
- 6. **Shlomai, A.**, Lubelsky, Y., Har-Noy, O., and Shaul, Y. 2009. The "Trojan horse" model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vector. *Biochem Biophys Res Commun* 390:619-623.
- 7. **Shlomai, A.**, and Shaul, Y. 2009. The metabolic activator FOXO1 binds hepatitis B virus DNA and activates its transcription. *Biochem Biophys Res Commun* 381:544-548.
- 8. Rechtman, M.M., Har-Noy, O., Bar-Yishay, I., Fishman, S., Adamovich, Y., Shaul, Y., Halpern, Z., and **Shlomai, A.** 2010. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha. *FEBS Lett* 584:2485-2490.
- 9. **Shlomai, A.**, Kariv, R., Leshno, M., Beth-or, A., Sheinberg, B., and Halpern, Z. 2010. Large-scale population analysis reveals an extremely low threshold for "non-healthy" alanine aminotransferase that predicts diabetes mellitus. *J Gastroenterol Hepatol* 25:1687-1691.
- 10. **Shlomai, A.**, Nutman, A., Kotlovsky, T., Schechner, V., Carmeli, Y., and Guzner-Gur, H. 2010. Predictors of pandemic (H1N1) 2009 virus positivity and adverse outcomes among hospitalized patients with a compatible syndrome. *Isr Med Assoc J* 12:622-627.
- 11. Ben-Shlomo, S., Zvibel, I., Shnell, M., **Shlomai, A.**, Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., and Fishman, S. 2011. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. *J Hepatol* 54:1214-1223.
- 12. Tchebiner, J.Z., Nutman, A., Boursi, B., **Shlomai, A.**, Sella, T., Wasserman, A., and Guzner-Gur, H. 2011. Diagnostic and prognostic value of thrombocytosis in admitted medical patients. *Am J Med Sci* 342:395-401.
- 13. Zelber-Sagi, S., Yeshua, H., **Shlomai, A.**, Blendis, L., Leshno, M., Levit, S., Halpern, Z., and Oren, R. 2011. Sampling variability of transient elastography according to probe location. *Eur J Gastroenterol Hepatol* 23:507-514.
- 14. Ben-Shlomo, S., Einstein, F.H., Zvibel, I., Atias, D., **Shlomai, A.**, Halpern, Z., Barzilai, N., and Fishman, S. 2012. Perinephric and epididymal fat affect hepatic metabolism in rats. *Obesity (Silver Spring)* 20:151-156.
- 15. **Shlomai, A.**, Rechtman, M.M., Burdelova, E.O., Zilberberg, A., Hoffman, S., Solar, I., Fishman, S., Halpern, Z., and Sklan, E.H. 2012. The metabolic regulator PGC-1alpha links hepatitis C virus infection to hepatic insulin resistance. *J Hepatol* 57:867-873.
- 16. Ben-Shlomo, S., Zvibel, I., Rabinowich, L., Goldiner, I., **Shlomai, A.**, Santo, E.M., Halpern, Z., Oren, R., and Fishman, S. 2013. Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis. *Dig Dis Sci.* 58(1):172-8

- 17. Zelber-Sagi, S., Lotan, R., **Shlomai, A.**, Webb, M., Harrari, G., Buch, A., Nitzan Kaluski, D., Halpern, Z., and Oren, R. 2012. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. *J Hepatol* 56:1145-1151.
- 18. Mouler Rechtman, M., Burdelova, E.O., Bar-Yishay, I., Ben-Yehoyada, M., Fishman, S., Halpern, Z., and **Shlomai, A.** 2013. The metabolic regulator PGC-1alpha links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus. *J Viral Hepat* 20:34-41.
- 19. **Shlomai, A.**, Halfon, P., Goldiner, I., Zelber-Sagi, S., Halpern, Z., Oren, R., and Bruck, R. 2013. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. *J Viral Hepat* 20:95-102. 20. Adamovich, Y., **Shlomai, A.**, Tsvetkov, P., Umansky, K.B., Reuven, N., Estall, J.L., Spiegelman, B.M., and Shaul, Y. 2013. The protein level of PGC-1alpha, a key metabolic regulator, is controlled by NADH-NQ01. *Mol Cell Biol*. 2013 May 6 (DOI:10.1128/MCB.01672-12)

#### **Reviews and Guidelines**

- 1. **Shlomai, A.**, and Shaul, Y. 2004. RNA interference--small RNAs effectively fight viral hepatitis. *Liver Int* 24:526-531.
- 2. Bar-Yishay, I., Shaul, Y., and **Shlomai, A.** 2011. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. *Liver Int* 31:282-290.
- 3. Sikuler, E., Ackerman, Z., Braun, M., Baruch, Y., Bruck, R., Safadi, R., **Shlomai, A.**, and Ben-Ari, Z. 2012. [Guidelines for diagnosis and management of cirrhotic ascites and its complications. The Israeli Association for the Study of the Liver]. *Harefuah* 151:705-708, 719.

### Case reports, Letters and Editorials

- 1. **Shlomai, A.**, Hershko, A.Y., Gabbay, E., and Ben-Chetrit, E. 2004. Clinical and radiographic features mimicking pulmonary embolism as the first manifestation of Takayasu's arteritis. *Clin Rheumatol* 23:470-472.
- 2. **Shlomai, A.**, and Guzner-Gur, H. 2010. Ectopic splenomegaly. *Intern Med J* 40:600.
- 3. **Shlomai, A.** 2012. Targeting late SV40 factor: Is the achilles heel of hepatocarcinogenesis revealed? *World J Gastroenterol* 18:6709-6711.

#### **Abstracts and Conferences**

- **1.**Inhibition of HBV expression and replication by RNA interference (oral). The first conference of the Israeli Society of Gene Therapy (ISGT), (12/02), the Weizmann Institute of Science (2003)
- **2.**Inhibition of HBV expression and replication by RNA interference (oral). The conference of the Israeli society for the study of liver diseases (2/03), Haifa, Israel.
- **3**.Inhibition of HBV expression and replication by RNA interference" (poster#180) The annual molecular biology of HBV conference, Bergemo, Italy (10/03)
- **4**.The "Trojan horse" model- delivery of anti HBV small interfering RNAs using a recombinant HBV vector (oral). The conference of the Israeli society for the study of liver diseases (2/04), Eilat, Israel

- **5.**A cross-talk between metabolic alterations in the liver and HBV gene expression (oral). The conference of the Israeli society for the study of liver diseases (3/06), Eilat, Israel
- **6.**Nutritional signals regulate HBV through the metabolic coactivator  $Pgc1\alpha$  (poster). The FASEB conference on "liver growth, development and disease", July 2006, Snowmass village, Colorado, USA.
- **7.**PGC-1 controls hepatitis B virus through nutritional signals (oral). The annual conference of the Israeli society of microbiology (ISM), Bar-Ilan University (2/07).
- **8**.Evidence that Hepatitis B virus interacts with hepatic metabolic circuits to induce major liver pathologies (oral). The annual conference of the Israeli society for the study of liver diseases (3/09 Kfar Bloom).
- **9.**Colitis- from diarrhea to DALM: new insights, new controversies (An invited lecture/case presentation). ASNEMGE/EAGE 6<sup>th</sup> European School of Gastroenterology (June 2009, Prague).
- **10.**Major metabolic circuits in the liver regulate hepatitis B virus and are apotential target for anti viral therapy" (Abstract 406, Hepatology 50;4 (suppl) 497A). The AASLD annual conference (October-November 2009, Boston, USA).
- 11. Nutritional cues regulate hepatitis B virus and are a potential target for anti viral therapy (oral). The annual conference of the Israeli society for the study of liver diseases (3/10, Kfar Bloom).
- **12.** Hepatitis B virus as a metabolovirus (invited speaker), department of microbiology, Sackler Faculty of Medicine, TAU (2010).
- **13.**Hepatitis B virus up-regulates its own coactivator PGC-1 alpha resulting in hepatic metabolic alterations" (Abstract 1429, Hepatology 52;4 (suppl) 1007 A). The AASLD annual conference (October-November 2010, Boston, USA).
- **14.** I. Anti cancer chemotherapy directly up-regulates hepatitis B virus via the metabolic coactivator PGC-1 $\alpha$ . II. Blood bile acids levels as a non-invasive tool to assess the severity of non-cholestatic liver diseases (oral). The annual meeting of the Israeli Society of Gastroenterology and Liver Diseases, (January 2011, Eilat).
- **15.** The metabolic regulator PGC-1 alpha links cancer chemotherapy to hepatitis B virus reactivation" (Abstract 1122, J Hepatol 2011;54:s444). The EASL annual meeting (March-April 2011, Berlin, Germany).
- 16. The metabolic regulator PGC- $1\alpha$  links HCV infection to hepatic insulin resistance" (Presented by Dr Ela Olga Burdelova) (poster). The Israeli Society of Microbiology fall workshop, Molecular and clinical aspects of viral infections (Kibutz Ein-Gedi, 1-3 December). (The poster was awarded an excellence prize).
- 17. The metabolic regulator PGC- $1\alpha$  links HCV infection to hepatic insulin resistance (oral). The annual meeting of the Israeli society of Gastroenterology and liver diseases, (January 2012, Eilat). (The abstract was awarded an excellence prize).
- 18. HBV induces its own coactivator PGC-1 $\alpha$  via cellular oxidative stress (presented by Dr Iddo Bar-Yishay), The annual conference of the Israeli Society for the study of the liver (3/12, Kfar-Blum). (The abstract was awarded an excellence prize).
- **19.** The metabolic regulator PGC-1α links Hepatitis C virus infection to hepatic insulin resistance (HEPATOLOGY, VOLUME 56, NUMBER 4 (SUPPL), poster #1050). The AASLD annual conference (Boston, November 2012).